AbbVie’s oncology segment is poised to deliver approximately 4% year-over-year sales growth in the fourth quarter, driven by uptake of its newer small-molecule and biologic therapies. Portfolio highlights include robust demand for its latest PD-1 inhibitor, which accounted for over $400 million in quarterly revenues, more than offsetting a 12% decline in Imbruvica sales. Management cited expanded label approvals in urothelial and gastric cancers, with combined sales of those indications doubling to $150 million, as key contributors to the segment’s resilience.

AbbVie has entered into a three-year voluntary pricing agreement with the federal government, agreeing to lower Medicaid net prices on its core branded medicines while committing $100 billion in U.S. research, development and capital expenditures over the next decade. In exchange, the company secured exemptions from existing import tariffs on key active pharmaceutical ingredients and protection from new price control mandates. The agreement covers products used by an estimated 16 million Americans annually, including immunology stalwarts and thyroid therapies under the TrumpRx direct-to-patient program.

In a landmark licensing pact with RemeGen, AbbVie paid $650 million upfront for exclusive rights to develop, manufacture and commercialize RC148 outside Greater China, with total milestone payments potentially reaching $4.95 billion based on regulatory and sales targets. Concurrently, AbbVie agreed to acquire a West Pharmaceutical Services facility in Tempe, Arizona, for $175 million. The transaction, expected to close in mid-2026, will add multiple production lines and 3.5 mL on-body injector technology to support next-generation immunology and neuroscience medicines. The company plans to invest in modernizing the site and hire approximately 200 employees, further strengthening its U.S. manufacturing footprint.